Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232024 · ClinicalTrials.gov registry record · Phase 3
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,296
- Enrollment target
NCT00232024: Completed Phase 3 study, sponsored by Novartis.
NCT00232024 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,296 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232024, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,296 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,296 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00232024 record still lists
NCT00232024 is an interventional study that assigns participants to a tested intervention. Its 1,296 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00232024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232024 about?
NCT00232024 is a clinical study titled "Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia". This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
What is the current status of trial NCT00232024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,296 participants. The study started on 2004-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00232024?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00232024?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00232024's enrollment target sits among peer trials
1,296 195th of 2000 higher than 1,806 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia